Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place from September 9-11, 2024 in New York City.

Longeveron's presentation is set for Tuesday, September 10, 2024, from 5:00 – 5:30 p.m. ET. Investors and interested parties can access the webcast through the "Events and Presentations" section of the company's website. A replay of the presentation will be available for 180 days following the conference.

This conference provides Longeveron with an opportunity to showcase its progress in developing cellular therapies for life-threatening and chronic aging-related conditions to a global investment audience.

MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26^th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.

Details for the Company’s presentation:

	Date:	Tuesday, September 10, 2024
	Time:	5:00 – 5:30 p.m. ET

The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

FAQ

When is Longeveron (LGVN) presenting at the H.C. Wainwright Global Investment Conference?

Longeveron (LGVN) is presenting on Tuesday, September 10, 2024, from 5:00 – 5:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference.

Where can I watch Longeveron's (LGVN) presentation at the H.C. Wainwright conference?

The webcast for Longeveron's (LGVN) presentation can be accessed through the "Events and Presentations" section of the company's website.

How long will the replay of Longeveron's (LGVN) conference presentation be available?

The replay of Longeveron's (LGVN) conference presentation will be available on the company's website for 180 days following the conference.

What type of company is Longeveron (LGVN)?

Longeveron (LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions.